<DOC>
	<DOCNO>NCT00002351</DOCNO>
	<brief_summary>To evaluate safety , tolerability , plasma concentration profile indinavir sulfate ( MK-639 ; Crixivan ) HIV-seropositive old child adolescent . To compare plasma concentration profile initial dose data historical group adult . To obtain preliminary data antiviral activity MK-639 .</brief_summary>
	<brief_title>A Study L-735,524 HIV-Positive Children Adolescents</brief_title>
	<detailed_description>Patients receive MK-639 14 one-third day . Repeat plasma sample collect 8 hour follow first last dose . Urine sample collect day 1 5 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positivity . No active opportunistic infection within past 30 day , superficial candidiasis oral cavity vagina . Body surface area least 1.0 sqm . Consent parent guardian . Prior Medication : Allowed : Aerosolized pentamidine . Topical antifungal . TMP / SMX . AZT . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant hepatic disease include HBsAg hepatitis C positivity . Significant neurologic disease loss intellectual ability , motor deficit , seizure disorder . Significant cardiac disease include dysrhythmia cardiomyopathy . Significant medical condition laboratory abnormality may pose additional risk patient study confound result . Has social situation may interfere study participation . Concurrent Medication : Excluded : Oral contraceptive . Patients follow prior condition exclude : History serious allergic drug reaction . History significant cardiac disease . Participation another clinical trial within past 4 week . Donated blood within past 4 week . Prior Medication : Excluded within past 4 week : Hematopoietic growth factor . Excluded within past 2 week : Antiretroviral agent zidovudine . Oral contraceptive . Prophylaxis opportunistic infection , aerosolize pentamidine , topical antifungal , TMP/SMX . Any medication unless approve Merck clinical monitor . Current illicit drug use .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 1995</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
</DOC>